DocDollars

Astrazeneca Pharmaceuticals LP

DE · United States · Reporting entity ID 100000000146

Total reported 2019–2025
$2.97B
#6 of 2,960 reporting companies — 3.6% of all reported industry payments
$455.9M in general payments across 3,228,979 records, plus $2.51B in research funding across 43,708 records.

How it breaks down

General payments $455,882,965
Research funding $2,513,126,992

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Astrazeneca Pharmaceuticals LP reported $2.97B to US doctors and teaching hospitals from 2019 to 2025, ranking #6 of 2,960 reporting companies. 85% of that was research funding and 15% general payments such as consulting, speaking, food and travel. 3,228,979 general payment records and 43,708 research records were filed.

Common questions about Astrazeneca Pharmaceuticals LP

How much has Astrazeneca Pharmaceuticals LP paid US doctors?

Astrazeneca Pharmaceuticals LP reported $2,969,009,957 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $455,882,965 in general payments, $2,513,126,992 in research funding.

How does Astrazeneca Pharmaceuticals LP rank among drug and device companies?

It ranks #6 of 2,960 reporting entities by total reported value, about 3.6% of all industry payments in the dataset.

Does a payment from Astrazeneca Pharmaceuticals LP mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.